PRTA - プロセナ （Prothena Corporation plc） プロセナPRTAのチャート
PRTAの企業情報
| symbol | PRTA |
|---|---|
| 会社名 | Prothena Corp Plc （プロセナ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 プロザナー（Prothena Corporation Public Limited Company）はグローバルなバイオ会社である。同社はタンパク質ミスフォールディングまたは細胞接着を伴う疾患の治療用の免疫療法の発見、開発、商業化に焦点を当てる。同社の抗体ベースの製品候補の臨床パイプラインは、アミロイド軽鎖（AL）アミロイドーシス（NEOD001）、パーキンソン病および他の関連シヌクレイノパチー（PRX002）、並びに乾癬および乾癬性関節炎を含む炎症性疾患（PRX003）とATTRアミロイドーシス（PRX004）を含む炎症性疾患を含む多様な適応症を対象とする。同社はトランスサイレチン（TTR）媒介性アミロイドーシス（ATTR）タンパク質のアミロイド形成性（疾患性）形態に選択的に結合するモノクローナル抗体を生成した。同社のパイプラインには、アミロイドまたは細胞接着に関連する疾患の前臨床モデルにおける抗体の有効性を試験する遅発発見段階プログラムも含まれる。 プロセナはアイルランドのバイオテクノロジ―会社。タンパク質のミスフォ―ルディングや細胞接着などに関連した疾患の治療に向けた抗体医薬品の発見と開発に従事する。研究開発パイプラインにはパ―キンソン病治療用のモノクロ―ナル抗体PRX002、ALおよびAAアミロイド―シス治療用の抗アミロイド抗体NEOD001などがある。 Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau (PRX005), TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Prothena’s wholly-owned programs include PRX004 for the potential treatment of ATTR amyloidosis, and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aß (Amyloid beta). |
| 本社所在地 | Adelphi Plaza Upper George's Street Dun Laoghaire Dublin 94080 IRL |
| 代表者氏名 | Lars G. Ekman ラース・エックマン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +353 1-236-2500 |
| 設立年月日 | 41153 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 125人 |
| url | www.prothena.com |
| nasdaq_url | https://www.nasdaq.com/symbol/prta |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -188.52400 |
| 終値（lastsale） | 12.47 |
| 時価総額（marketcap） | 496765344.92 |
| 時価総額 | 時価総額（百万ドル） 517.08220 |
| 売上高 | 売上高（百万ドル） 0.95400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 32.34420 |
| 当期純利益 | 当期純利益（百万ドル） -209.17700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Prothena Corporation PLC revenues decreased 98% to $506K. Net loss increased from $53.1M to $108.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - gross increase of 12% to $61.3M (expense) General and administrative - gross increase of 16% to $16.8M (expense). |
PRTAのテクニカル分析
PRTAのニュース
Prothena adds former FDA neuro chief Billy Dunn to director board 2023/05/17 16:13:55 Seeking Alpha
Alzheimer''s drug developer Prothena (PRTA) announced Tuesday that Billy Dunn, who previously led the FDA''s Office of Neuroscience, is joining its board. Read more here.
Prothena Corporation plc: Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors 2023/05/16 20:12:00 Finanz Nachrichten
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today…
Prothena Biosciences'' Unique Approach To Protein Misfolding Could Be The Future 2023/05/07 06:28:01 Seeking Alpha
Prothena''s recent collaboration with Walgreens is expected to drive recruitment for Prothena''s ongoing ASCENT-2 safety and tolerability trial of PRX012. Click here to read more.
BofA Securities maintains Prothena at Buy with a price target of $85.00 2023/05/05 16:23:37 Investing.com
https://www.investing.com/news/pro/prothena-corp-receives-investment-bank-analyst-rating-update-3074646
Recap: Prothena Corp Q1 Earnings 2023/05/04 21:05:33 Benzinga
Prothena Corp (NASDAQ: PRTA ) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Prothena Corp beat estimated earnings by 5.32%, reporting an EPS of $-0.89 versus an … Full story available on Benzinga.com
Prothena: I''m Not A Buyer At A $3 Billion Valuation 2023/02/08 11:32:52 Seeking Alpha
Prothena’s pipeline has several high-value assets which may trigger several milestone payments and royalties. See why I am rating PRTA stock as a Sell.
Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/02/03 21:06:00 Finanz Nachrichten
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today ann…
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/02/03 21:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prothena says Alzheimer’s candidate was safe in early-stage trial (NASDAQ:PRTA) 2023/01/31 21:56:29 Seeking Alpha
Prothena (PRTA) announced Tuesday that PRX005, an Alzheimer''s candidate it develops with Bristol Myers (BMY), was safe and well tolerated in a Phase 1 trial Read the full story here.
Prothena Corporation plc: Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer''s Disease 2023/01/31 21:12:00 Finanz Nachrichten
Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this p…
These strategies will help Prothena Corporation plc (PRTA) succeed 2022/12/01 15:32:00 US Post News
In Wednesday’s session, Prothena Corporation plc (NASDAQ:PRTA) marked $62.51 per share, up from $58.12 in the previous session. While Prothena Corporation plc has overperformed by 7.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRTA rose by 24.65%, with highs and lows ranging from $65.35 to […]
This Insider Just Sold Shares of Prothena Corp PLC 2022/11/27 18:30:05 GuruFocus
Related Stocks: PRTA ,
Roche''s Alzheimer''s Drug Fails In Phase 3; Here''s The Fallout For Biogen, Lilly, Prothena And Others 2022/11/14 14:17:46 Investor''s Business Daily
Roche said its experimental Alzheimer''s treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.